Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma | Journal of Translational Medicine BioMed Central Open Access Phase II trial of Modified Vaccinia Ankara MVA virus expressing 5T4 and high dose Interleukin-2 IL-2 in patients with metastatic renal cell carcinoma Howard L Kaufman 1 Bret Taback1 William Sherman1 Dae Won Kim1 William H Shingler2 Dorota Moroziewicz1 Gail DeRaffele1 Josephine Mitcham1 Miles W Carroll3 Richard Harrop2 Stuart Naylor2 and Seunghee Kim-Schulze1 Address Tumor Immunology Laboratory Division of Surgical Oncology Columbia University New York NY USA 2Oxford BioMedica . Ltd. Oxford UK and 3R2D Ltd Wantage UK Email Howard L Kaufman - hlk2003@ Bret Taback - bt2160@ William Sherman - whs4@ Dae Won Kim - kimdw1031@ William H Shingler - Dorota Moroziewicz - dm2110@ Gail DeRaffele - gd2023@ Josephine Mitcham - jm2124@ Miles W Carroll - MWCarroll01@ Richard Harrop - Seunghee Kim-Schulze - sk2254@ Corresponding author Published 7 January 2009 Received 10 November 2008 Journal of Translational Medicine 2009 7 2 doi l479-5876-7-2 Accepted 7 January 2009 This article is available from http content 7 1 2 2009 Kaufman et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Interleukin-2 IL-2 induces durable objective responses in a small cohort of patients with metastatic renal cell carcinoma RCC but the antigen s responsible for tumor rejection are not known. 5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A modified vaccinia virus Ankara MVA encoding 5T4 was .
